Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells

Vγ2Vδ2 T cell-based immunotherapy has benefited some patients in clinical trials, but the overall efficacy is low for solid tumor patients. In this study, a bispecific antibody against both PD-L1 and CD3 (PD-L1 x CD3), Y111, could efficiently bridge T cells and PD-L1 expressing tumor cells. The Y111...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Rui, Shen, Susu, Gong, Cheng, Wang, Xin, Luo, Fang, Luo, Fengyan, Lei, Yang, Wang, Zili, Xu, Shasha, Ni, Qian, Xue, Yan, Fu, Zhen, Zeng, Liang, Fang, Lijuan, Yan, Yongxiang, Zhang, Jing, Gan, Lu, Yi, Jizu, Zhou, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141752/
https://www.ncbi.nlm.nih.gov/pubmed/34040604
http://dx.doi.org/10.3389/fimmu.2021.654080

Ejemplares similares

Ejemplares similares